Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Cardinal Health (NYSE: CAH) announced the election of David C. Evans as an independent director, effective July 1. Mr. Evans brings extensive financial expertise and operational experience, having served as interim CFO of Cardinal Health and CFO at Battelle Memorial Institute and Scotts MiracleGro. His board roles include positions at Scotts MiracleGro and the Siegel Rare Neuroimmune Association. The board chair, Gregory Kenny, expressed confidence in Evans' leadership during periods of change, emphasizing the importance of his insights for future growth strategies.